NCT03338426

A Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and Dyslipidemia

A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and Dyslipidemia

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 133 (actual)
• Sponsor: Boryung Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 19 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The objective of this clinical study is to evaluate the efficacy and safety by comparing the fimasartan/atorvastatin treatment group to the fimasartan/placebo treatment group and the placebo/atorvastatin treatment group respectively at Week 8 in patients with essential hypertension and dyslipidemia.

Conditions

• Essential Hypertension, Dyslipidemia

Interventions

Type	Name	Description
DRUG	Fimasartan 120mg	Fimasartan 120mg will be administrated once daily for 8 weeks treatment period
DRUG	Atorvastatin 40mg	Atorvastatin 40mg will be administrated once daily for 8 weeks treatment period
DRUG	Placebo for Fimasartan 120mg	Placebo for Fimasartan 120mg will be administrated once daily for 8 weeks treatment period
DRUG	Placebo for Atorvastatin 40mg	Placebo for Atorvastatin 40mg will be administrated once daily for 8 weeks treatment period

Timeline

• Start date: 2018-01-15
• Primary completion: 2019-04-22
• Completion: 2019-04-22
• First posted: 2017-11-09
• Last updated: 2019-11-05

Locations

1 site across 1 country: South Korea